Steroid treatment of acute graft-versus-host disease grade I: A randomized trial by Bacigalupo, Andrea et al.
haematologica | 2017; 102(12) 2125
Received: May 11, 2017.
Accepted: September 22, 2017.
Pre-published: September 29, 2017.
©2017 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-
mercial purposes is not allowed without permission in writing
from the publisher.
Correspondence: 
apbacigalupo@yahoo.com
Ferrata Storti
Foundation
EUROPEAN
HEMATOLOGY
ASSOCIATION
Haematologica 2017
Volume 102(12):2125-2133
ARTICLECell Therapy & Immunotherapy
doi:10.3324/haematol.2017.171157
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/102/12/2125
Patients with acute graft-versus-host disease (GvHD) grade I wererandomized  to an observation arm (n=85) or to a treatment arm(n=86) consisting of  6-methylprednisolone 1 mg/kg/day, after
stratification for age and donor type. The primary end point was devel-
opment of grade II-IV GvHD. The cumulative incidence of grade II-IV
GvHD was 50% in the observation arm and 33% in the treatment arm
(P=0.005). However, grade III-IV GvHD was comparable (13% vs.
10%, respectively; P=0.6), and this was true for sibling and alternative
donor transplants. Moderate/severe chronic GvHD was also compara-
ble (17% vs. 9%). In multivariate analysis, an early interval between
transplant and randomization (<day +20) was the only negative predic-
tor of  grade III-IV GvHD. Patients in the observation arm had less
infectious bacterial episodes (12 vs. 25; P=0.04), less severe infectious
fungal episodes (0 vs. 3; P=0.04), and less severe adverse events (3 vs.
11; P=0.07).  At five years, non-relapse mortality  was 20% versus 26%
(P=0.2), relapse-related mortality  25% versus 21%, and actuarial sur-
vival was 51% versus 41% (P=0.3) in the observation and treatment
arms, respectively. In multivariate analysis, advanced disease phase,
older age and an early onset of GvHD were significant negative predic-
tors of survival, independent of the randomization arm. In conclusion,
steroid treatment of acute grade I GvHD prevents progression to grade
II but not to grade III-IV GvHD, and there is no effect on non-relapse
mortality  and survival. Patients treated with steroids are at a higher
risk of developing infections  and have more adverse events. (Trial reg-
istered as EUDTRACT 2008-000413-29).
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ABSTRACT
Introduction
There is uncertainty as to whether grade I acute graft-versus-host disease
(GvHD), that is a skin rash over less than 50% of the body surface, without liver
or gut involvement, should be treated or not. In three  prospective trials of first-
line treatment, also patients with grade I acute GvHD (aGvHD) were enrolled;1-3
however, most Centers would probably treat only GvHD of grade II or over. One
argument in favor of steroid treatment would be early intervention, thus possibly
preventing progression to more severe GvHD. This is a general rule of medicine,
but there is no evidence that this is also the case in patients with  aGvHD.1,2  In one
randomized  study back in 1998, the Gruppo Italiano Trapianti di Midollo Osseo
(GITMO) had shown that early intervention with high-
dose steroid treatment (10 mg/kg) was equally effective as
a conventional dose of steroids (2 mg/kg) in first-line treat-
ment of aGvHD.3 In that study, the proportion of patients
who progressed to grade III-IV was similar in the two
groups, despite a median interval between transplant and
treatment of 12 days, arguing against the hypothesis that
early aggressive intervention would be more effective
than standard therapy and would be able to modify the
natural disease course.3 Similar results were seen in a more
recent prospective randomized trial, once again compar-
ing  two different doses of steroids as first-line treatment,
and again showing no difference in the rate of progression
to severe GvHD.4 In addition, steroids cause immune defi-
ciency and promote infectious complications.5  
On the other hand,  early treatment of GvHD could be
beneficial. In a retrospective study of unrelated donor
transplants in two different Centers, non-relapse mortality
(NRM) was lower in one Center using anti-thymocyte
globulin (ATG) for GvHD prophylaxis and steroid treat-
ment of grade I aGvHD.6 
In any case, whether grade I GvHD should be treated or
not has not been tested in a prospective trial, and this led
GITMO to undertake this trial. The aim was how to cal-
culate the lowest and highest success rate. We used data
from the  previous GITMO study:2 25% of patients with
grade I GvHD treated with 6methylprednisolone
(6MPred) 2 mg/kg progressed to grade II-IV GvHD. We
hypothesized that patients left untreated would have
twice the risk of progression to grade II-IV GvHD, and 170
patients were needed to test this hypothesis. 
We report the results of this trial in patients with grade
I GvHD, randomized to receive steroid treatment or no
treatment.
Methods
Study design
This is a Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
study (study name: RAMP08; registered as  EUDTRACT N 2008-
000413-29). The study was conducted according to Good Clinical
Practice (GCP) and the Declaration of  Helsinki. The study proto-
col was approved by all local ethical committees. Data entry was
made by electronic CRF provided by Clinical Research Technolgy
(CRT), Naples, Italy. The study is an open label multicenter, phase
III randomized study comparing no treatment versus treatment
with 6-methylprednisolone (6MPred) 1 mg/kg per day for trans-
planted patients with grade I aGvHD according to Gucksberg's
criteria.7 Randomization was managed centrally via the web  in a
1:1 ratio. Patients were randomized using a dynamic randomiza-
tion algorithm, with minimization of differences between arms A
and B to no more than 2 patients overall and 3 patients per strata.
Patients were stratified according to  phase (early/advanced) and
donor type (matched sibling/alternative donors). We applied a
modified intention-to-treat analysis, and all patients with at least
one day of follow up were analyzed in the arm to which they had
been allocated: 173 patients were randomized,  between July 2009
and August 2014, and 171 were analyzed. The study outline is
shown in Figure 1. Patients randomized to the observation arm
were left untreated. Patients progressing to grade  II-IV  GvHD
were considered to have reached the primary end point of the
study, independent of the interval from randomization, and were
treated according to standard procedures of each Center. Patients
randomized to observation and not progressing were followed up.
Patients randomized to treatment received 6MPred 1 mg/kg/day
for five days. Patients progressing to grade  II-IV  GvHD, had
reached the primary end point of the sudy and were treated
according to the policy of each Center.  If GvHD did not progress,
6MPred was tapered as follows: 0.75 mg/kg/day on days 6-10, 0.5
mg/kg/day  on days 11-15, 0.25 mg/kg/day on days 16-20, 0.12
mg/kg/day on days 21-30, and discontinued on day +30.
End points
The primary end point was the cumulative incidence of patients
progressing to grade II-IV aGvHD. Secondary end points were:
proportion of patients with grade  III-IV GvHD, proportion of bac-
terial infections, viral infection, fungal infections, number of
adverse events and severe adverse events, cumulative incidence of
non-relapse mortality (NRM), cumulative incidence of relapse,
proportion of patients developing chronic GvHD (limited and
extensive), actuarial overall survival (OS). 
Inclusion and exclusion criteria
Study inclusion criteria were:  age 0-70 years, having received
an allogeneic stem cell transplant  for malignant or non-malignant
diseases, developing a skin rash over 10-49% of the body surface
within the previous 48 hours, having received an unmanipulated
graft from any donor type, and  not having received previous treat-
ment with steroids. Signed informed consent was obtained from
adults or, in the case of pediatric cases, their tutors. Conventional
GvHD prophylaxis was given to all patients with cyclosporin
methotrexate, with the addition of ATG for unrelated donors, and
post-transplant cyclophosphamide (PT-CY) for the small number
(n=15) of HAPLO grafts. A skin biopsy , was recommended but
A. Bacigalupo et al.
2126 haematologica | 2017; 102(12)
Table 1. Clinical data of patients randomized.
Observation Treatment P
N 85 86
Age 46 (1-69) 38 (0.4-68) 0.06
Sex M/F 37/48 35/51 0.7
Diagnosis 
SAA 2 2 0.7 
AML 41 34
ALL 16 23
CML 3 1
MDS 5 7
Myelofibrosis 4 5
Myeloma 3 6
CLL 3 2
NHL 4 3
HD 2 1
Other 2 2
Disease phase:early  43 (53%) 38 (47%) 0.7
Donor type
Matched SIBS 36 (42.4%) 34 (39.5) 0.1
UD 36 (42.4%) 44 (51.2%)
HAPLO 6 (7.1%) 7 (8.1%
CB 7 (8.2%) 1  (1.2%)
Conditioning MA/RIC 64/21 61/25 0.8
M/F: male / female; SAA: severe aplastic anemia; AML: acute myeloid leukemia; ALL: acute
lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syn-
dromes; CLL: chronic lymphocytic leukemia; NHL: non-Hodgkin lymphoma; HD: Hodgkin
disease; UD: unrelated donor; SIBS: siblings; HAPLO: HLA haploidentical donors; CB: cord
blood; MA: myeloablative conditioning.; RIC: reduced intensity conditioning.
not mandatory; centralized histopathology was provided (D
Massi, Florence, Italy). 
Exclusion criteria were: life-threatening infections, evidence of
hematologic relapse, investigational drugs for GvHD prophylaxis,
patients on steroid treatment (>0.5 mg/kg for 48 hours), grade II-
IV GvHD. Progression to gut GvHD, but not liver GvHD, was
confirmed by histology. 
Patients’ characteristics
Clinical characteristics of the two groups (observation/treat-
ment)  are outlined in Table 1. Patients were well balanced in
terms of diagnosis (P=0.7): the most frequent diagnosis was acute
myeloid leukemia (AML) (n=75), followed by acute lymphoblastic
leukemia (ALL) (n=39), and myelodysplastic syndromes (MDS)
(n=12). Median age for observation/treatment was 46 years (1-69)
versus 38 years (0.4-68) (P=0.06). The proportion of patients over
50 years was 51% in the observation arm and 49% in the treat-
ment arm (P=0.8). Donor type was: HLA identical siblings n=36
and n=34, unrelated cord blood (CB) n=7 and n=1, unrelated
donor (UD) n=36 and n=44, and haploidentical family donors
(HAPLO) 6 and 7 (P=0.1) in the observation and treatment arms,
respectively. The proportion of 1 antigen mismatched unrelated
donors was 7 and 9,  respectively (P=0.9). Disease phase was clas-
sified as early in 43 observation arm patients and in 38 treatment
arm patients (P=0.7). The conditioning regimen was myeloabla-
tive in most patients (n=64 and n=61, respectively; P=0.8). 
Supportive care
Antibacterial prophylaxis with quinolones was given during the
neutropenic phase. All Centers used PJV prophylaxis with cotri-
moxazole and monitored cytomegalovirus (CMV) reactivation by
PCR or antigenemia twice weekly. Pre-emptive therapy was given
in case of CMV reactivation. Epstein Barr Virus (EBV) was moni-
tored by PCR weekly and treated pre-emptively if positive.
Aspergillus antigenemia with galactomannan was also monitored
weekly; diagnosis of invasive fungal disease was performed by
standard criteria and treated accordingly. Specific infectious dis-
ease policies were performed according to standard procedures of
each Center. 
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Figure 1. Study outline. Patients randomized to the observation (n=85) or treatment  (n=86) arms all went forward for analysis. Two patients were not evaluable
because essential data were missing (1 observation arm; 1 treatment arm). 6MPred: 6 mthylprednisolone; FU: follow up.
Table 2. Patient outcome.
Observation Treatment P
N 85 86
Interval transplant-random (days) 20 (4-120) 20 (3-102) 0.5
Interval random-GvHD II-IV (days) 3 (0-37) 9 (0-63) 0.03 
GvHD II-IV (n. pts) 44 29 0.01
GvHD III-IV (n. pts) 11 9 0.6
Chronic GvHD moderate/severe 10 15 0.3
Steroid dose mg/kg <100 days 9.5 (0-105) 24 (13.5-180) 0.01
Causes of death
GvHD 9 13 0.5
Infections 7 9
Toxicity 1 1
Relapse 20 16
Random: randomization; GvHD: graft-versus-host disease; N, n.: number; pts.: patients.
Statistical analysis
Analysis of the primary end point was performed using the
cumulative incidence (CI) of grade II-IV GvHD, calculated with
mortality due to any cause as a competing risk. NRM was the
competing risk for relapse-related death (RRD) and vice versa. Gray
test was used to calculate difference between CI curves. Survival
was calculated with Kaplan Meier curves, and the log rank test
was used to test for difference  between survival curves. Cox test
was used for multivariate analysis. χ2 tables, Fisher exact test, and
2-sample t-test were used as appropriate; these statistical analyses
were carried out using NCSS10 for Windows.
Infections and adverse events  within day 100 from randomiza-
tion in the two arms were assessed using Poisson or Negative
Binomial (NB) regression model. Each infection type was consid-
ered as a single dependent variable and the decision on whether to
use the Poisson or the NB model was based each time on a
Likelihood-ratio test for overdispersion of the dependent variable
considered. The treatment group indicator was considered as
independent variable and the likelihood-ratio test was used to test
the association with infections. The total follow up of each patient
was considered as an exposure variable into the model. Stata (v.14)
was used for the computation.
Sample size calculation was made using data from a  previous
GITMO study:2 25% of patients with grade I GvHD treated with
6methylprednisolone (6MPred) 2 mg/kg, progressed to grade II or
over GvHD. We hypothesized that patients left untreated would
have twice the risk of progression to grade II-IV GvHD; 170
patients were needed to reject the null hypotesis with a power of
90%. 
Results
Primary end point and GvHD
The cumulative incidence (CI) of acute GvHD grade II
was 50% in the observation arm and 33%  in the treat-
ment arm (P=0.005) (Figure 2). This difference was more
pronounced in sibling donor grafts  (SIB) (61% vs. 32%;
P=0.01), as compared to alternative donor grafts  (ALT)
(42% vs. 33%; P=0.1). For patients who progressed, the
interval between randomization and progression was sig-
nificantly shorter in the observation arm  compared to the
treatment arm (3 vs. 9 days; P=0.03) (Table 2). Figure 3 out-
lines the CI of grade III-IV  GvHD in the observation 
versus the treatment arms (13% vs. 10%; P=0.6); it was
seen in 7 vs. 4 sibling grafts, and in 4 vs. 5 alternative donor
grafts, respectively (P=0.8). It was seen more frequently in
patients randomized before day 20 from transplant (n=88,
17%) as compared to patients randomized later (n=83,
6%) (P=0.02) irrespective of randomization to the obser-
vation or treatment arms: 18% vs. 16% for early GvHD
(<day 20), and 7% vs. 5%, for late GvHD  (day 20).
Moderate/severe chronic GvHD was comparable and was
diagnosed in 10 patients in the observation arm versus 15
in the treatment arm (P=0.3). 
Greatest severity of >grade 1 GvHD
Skin GvHD, stage 2, 3 was diagnosed respectively in
22, 1 observation vs. 6, 2 treatment patients; liver GvHD
stage 1,2, 3, was diagnosed in 4, 3, 1 observation vs. 7, 0,
0 treatment patients; gut GvHD stage 1, 2, 3, 4, was diag-
nosed respectively in 10, 3, 3, 1 observation vs. 3, 2, 3, 1
treatment  patients. 
Steroid dose and additional treatment
The median cumulative dose of 6MPred received in the
first 100 days was 9.5 mg/kg (range 0-105) and 24 mg/kg
(range 13-180) in the observation and treatment arms,
respectively (P=0.01) (Table 2). Of the 86 patients in the
treatment arm, 57 (66%) were off steroids by day +30,
whereas 29 were on steroids having progressed to grade
II-IV GvHD. Of the 85 patients in the observation arm, 41
(48%) never received steroids. The use of a second
immunosuppressive drug for GvHD in addition to corti-
costeroids was reported in 27 and 17 treatment and obser-
vation arms, respectively (P=0.08); administration of a
third drug was reported in 12 and 7 patients  (P=0.2) and
a fourth drug in 4 and 2 patients, respectively (P=0.4). The
second drug included mycophenolate mophetil (MMF) (in
6 and 7 patients, respectively), extracorporeal photophere-
A. Bacigalupo et al.
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Figure 2. Cumulative incidence of grade II-IV
acute graft-versus-host disease (GvHD) in
patients allocated to no treatment (observa-
tion) or treatment with prednisolone 1 mg/kg
(treatment).
P=0.005
sis (ECP) (12 and 4 patients, respectively), or  infliximab,
etanercept, rituximab, basiliximab, sirolimus, anti-CD26
antibody, in a few patients each. The third added drug
included ECP (3 and 2 patients, respectively), MMF (5 and
1, respectively), etanercept or anti-CD26 antibody. The
fourth added drug included MMF and ECP. 
Infections and adverse events
A summary of the adverse events in the two randomiza-
tion arms in the first three months of treatment is shown
in Table 3. The observation arm had less bacterial, fungal
and CMV infections compared to the treatment arm;
other adverse events and other severe adverse events were
also fewer in the observation arm (Table 3), although
these were mainly not statistically significant. Other
adverse events were reported in 17 and 33 patients in the
two arms, respectively (P=0.11), of which   3 and 11,
respectively, were classified as severe (P=0.07). Adverse
events included steroid-associated diabetes (0 vs. 9), acute
renal failure (2 vs. 2), cystitis (5 vs. 5), hip necrosis (0 vs. 2),
multi-organ failure (0 vs. 2), respiratory failure (0 vs. 3), and
thrombosis (0 vs. 2) in the observation and treatment
arms, respectively. Median blood counts were comparable
on day +60 from randomization between the two arms.
On day +60, chemistry results in the observation and
treatment arms were also comparable. 
Non-relapse mortality
The 5-year CI of NRM was 20% (observation arm) ver-
sus 26% (treatment arm) (P=0.2) (Figure 4), and was com-
parable also after stratifying patients for age: <40 years
(12% vs. 19%) and >40 years (28% vs. 34%). In univariate
analysis, there was a very strong influence of the interval
between transplant and randomization on NRM: median
interval 20 days, CI of NRM 31% versus 18% (P=0.0006)
for patients randomized before or after day +20 from
transplant, respectively. For early randomization (<20
days from transplant) NRM was 24% vs. 46% (P=0.02) in
observation versus treatment patients, due to an excess of
infections in the treatment arm (2 vs. 8); for late random-
ization (>20 days) NRM was comparable in the two arms
(22% and 14%; P=0.3). 
Relapse-related death and survival
Relapse-related death  was 25% in patients in the obser-
vation arm versus 21% in patients in the  treatment arm
(Figure 5); patients with early disease had a significantly
lower probability of RRD in univariate analysis (RR 0.3,
P=0.006). RRD was unaffected by the interval between
Steroid treatment of GvHD grade I 
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Figure 3. Cumulative incidence of grade III-IV
acute graft-versus-host disease (GvHD) in
patients allocated to no treatment (observa-
tion) or treatment with prednisolone 1 mg/kg
(treatment).
Table 3. Infectious episodes and adverse events in the two arms <100
days from randomization.
Observation Treatment P*
N 85 86
FU days at 100 days 8040 7934
FU days/patient 94.5 92.2
Bacterial infections 12 25 0.045
Severe bacterial inf. 3 8 0.16
Lethal bacterial inf. 2 5 0.29
Fungal infections 8 8 0.94
Severe fungal inf. 0 3 0.047
Lethal fungal inf. 0 2 0.11
CMV 63 84 0.48
Severe CMV inf. 3 3 0.94
Lethal CMV infections 0 3 0.046
Other viral infections 24 15 0.32
PTLD 2 1 0.53
Other AE 17 33 0.11
Other severe AE 3 11 0.077
Lethal AE 0 4 0.041
One patient can have more than one infectious episode or adverse event. FU: follow
up; AE: adverse events; inf: infections; CMV: cytomegalovirus; PTLD: post transplant
lymphoproliferative disease. *P-value: Poisson or Negative Binomial (NB) regression
model (see Statistical Analysis section).
P=0.6
transplant and randomization. Actuarial 5-year survival
was 51% versus 41% in the observation and treatment
arms, respectively (P=0.3) (Figure 6). Predictors of survival
in univariate analysis were younger age, early disease
phase, and randomization beyond day +20 from trans-
plant. Causes of death in the two study groups were:
GvHD in 9 versus 13 patients, infection in  7 versus 9
patients, toxicity  in 1 patient in each group, and leukemia
relapse in 20 versus 16 patients (P=0.9) (Table 2). There
was no significant difference in NRM  between different
Centers (P=0.5). 
Skin biopsies
A skin biopsy to prove or disprove skin GvHD was not
mandatory for eligibility in this trial. It was performed
before randomization and reviewed centrally by one of
the Authors (DM) in 38 patients. Of these, 36 (95%) were
compatible with  aGvHD (proven, probable, and possible
in 9, 15 and 12 patients, respectively); these were equally
distributed among  the  treatment and observation arms
(P=0.7).
Multivariate analysis
Progression to grade II-IV  GvHD was predicted in a
Cox analysis by age  over 20 years (P=0.003) or 40 years
(P=0.005), and randomization to the observation arm
(P=0.02) (Table 4). A short interval between transplant and
randomization (< 20 days), was the only variable predict-
ing progression to grade III-IV GvHD (RR  0.4, 95%CI:
0.12-0.98; P=0.04) and was also associated with a higher
risk of death (P=0.006). Survival was also predicted by
patients' age and disease phase. NRM was predicted only
by age over 20 years (RR 2.8, 95%CI: 0.88-9.18; P=0.07)
and age over 40 years (RR 3.0, 95%CI: 0.99-9.67;
P=0.051), and by early onset of GvHD before day +20
from transplant (RR 2.38, 95%CI: 1.06-4.0; P=0.03).
Discussion
Treatment of aGvHD remains a difficult issue, despite
several decades of studies and the many immunosuppres-
sive/immunomodulating agents tested.8 There are difficul-
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Table 4. Multivariate analysis. 
GvHD II-IV Overall survival
Base Compared RR 95% CI P RR 95%CI P
Age (y) <20 >20 3.6 1.03-12.8 0.04 2.4 1.09-5.58 0.02
>40 5.6 1.71-18.6 0.004 2.9 1.28-6.13 0.009
Sex M F 0.9 0.8 0.9 0.9
Donor ALT SIB 1.2 0.4 0.8 0.4
Phase ADV EARLY 0.6 0.1 0.5 0.35-0.9 0.02
Dx AL Other 0.9 0.8 1.1 0.6
SC source BM PB 0.7 0.3 0.9 0.8
CB 0.4 0.4 0.4 0.3
Rand OBS TREAT 0.5 0.35-0.99 0.04 1.4 0.1
Int.Tx-Rand <20 >20 dd 0.7 0.2 0.4 0.26-0.71 0.001
Base: baseline value; Compared: compared value; RR: relative risk; CI: Confidence Interval; y: years; M: male; F: female; SC: stem cell; ADV: advanced; BM: bone marrow; PB: periph-
eral blood; CB: cord blood; P: P-value; GvHD graft-versus-host disease; Rand: randomization group; OBS: observation; TREAT: treatment; Dx: diagnosis; AL: acute leukemia; Int. Tx-
Rand: interval in days (dd) between stem cell transplantation and randomization;  ALT: alternative donor; SIB: identical sibling. 
Figure 4. Comparable cumulative incidence of non-
relapse mortality (NRM) in the two randomization
groups.
P=0.2
ties not only in the treatment, but problems start with
staging of involved organs and overall grading of the dis-
ease, with several possible grading options  and a degree
of variability  according to the assessor.7-13  Despite differ-
ences in grading, and the difficulty in assessing response
rates, it is recognized that mortality increases with
increasing GvHD severity, and this is true both in the
short and in the long term.14 In a large group of patients
(n=4174), NRM at three years was 21% for grade 0-I
aGvHD, 32% for grade II, 60% for grade III,  and 89% for
grade IV; the corresponding 3-year OS  was 79%, 64%,
37% and 10%, respectively.14 This study exemplifies on
one hand, the major impact of aGvHD grading on the out-
come of allogeneic transplants, and on the other, the lack
of effective treatment when the disease is beyond grade II.
In keeping with the latter observation, a recently devel-
oped risk score for aGvHD identifies patients at high risk
of mortality according to the number of involved organs
and the severity of GvHD at onset.13 Mortality at six
months is 22% for standard-risk and 44% for high-risk
GvHD.13  A set of GvHD biomarkers  have recently been
described; these identify at the onset of the disease severe
cases with a high risk of mortality eligible for early inter-
vention.15
It would thus seem reasonable to try and prevent pro-
gression of aGvHD, and this may be achieved if aGvHD is
treated at a very early stage (earliest being grade I, or a
skin rash involving <50% of the body surface). We, there-
fore, asked whether steroid treatment of grade I GvHD
would be beneficial, and we selected evolution to grade II
or more as the primary end point of the study. Patients
randomized in the observation arm would become eligi-
ble for treatment when diagnosed as grade II GvHD, also
if this occurred 24 hours after randomization. This facili-
tated  the informed consent procedure with the patients
since there would be no delay in treatment once the dis-
ease had progressed to grade II. As expected, patients ran-
domized to receive treatment at diagnosis of grade I
GvHD had a significantly lower probability to progress to
grade II or more GvHD  compared to untreated patients
(33% vs. 50%). The fact that patients in the observation
arm, grafted from identical siblings, had a higher propor-
tion of grades II-IV GvHD (61%) compared to patients in
the observation arm receiving alternative donor grafts
(44%) can be explained by the fact that, in the latter,
GvHD prophylaxis included either ATG or PT-CY, in addi-
tion to CyA and MTX (UD grafts) or CyA and mycophe-
nolate (HAPLO grafts). The unexpected  finding was that
the CI of patients progressing to severe (grade III-IV)
GvHD was comparable in the two groups (13% vs. 10%).
Therefore, the primary end point of the study was
reached, but this was due to skin GvHD progressing from
stage II to stage III in the observation arm (22 observation
vs. 6 treatment patients) and stage 1 gut GvHD (10 obser-
vation vs. 3 treatment patients). On the other hand,
patients with stage II-IV gut GvHD were comparable in
the two randomization groups (7 and 6, respectively), and
liver GvHD was seen in a few patients only. 
When looking at adverse events, we found that patients
in the treatment arm had more infections and more
adverse events than observation patients, in particular,
bacterial infections, severe fungal infections, and CMV
reactivation. As a consequence of similar severe GvHD
and more infections, NRM was  20% in the observation
versus 26% in the treatment arm, and  survival at five years
was 51% versus 41%,  respectively. In a multivariate Cox
analysis, there was a trend for inferior survival (P=0.09) in
the treatment arm, despite a median younger age (38 vs.
46 years). 
Other studies have tested early treatment of GvHD.2-4
Etanercept and topical steroids have been reported by
Gatza et al.16  in grade I GvHD. Of the 34 patients enrolled
in that study,  3%  progressed to grade III-IV, significantly
lower than another group of patients receiving topical
steroids alone, 18% of whom progressed to grade III-IV
GvHD.16 Although Gatza et al. suggested that etanercept
was able to modify the natural course of the disease, 
2-year NRM  was 19%,16 comparable to the 20% NRM of
our observation arm, and  the 26% of our treatment arm.
Another non-steroid approach was tested propectively,
randomizing patients to receive or not  2.5 mg/kg ATG, on
day +7 after an alternative donor transplant.17 Grade III-IV
GvHD was significantly reduced in the ATG group  (5%)
compared to the untreated group (15%), though NRM
was only marginally reduced from 35% to 29% (P=ns).17
Finally, high-dose cyclophosphamide post transplant is
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Figure 5. Comparable cumulative incidence of
relapse-related death (RRD) in the two randomiza-
tion groups.
P=0.6
being widely and successfully used to prevent severe
GvHD,18-20 but again this is given very early (day +3) and
possibly interfers with the activation phase of T cells
rather than with the effector phase. 
We found a strong association of early GvHD with
GvHD severity and survival. Patients developing grade I
GvHD within day +20 from transplant had a higher prob-
ability (RR 2.7) of developing grade III-IV GvHD, as com-
pared to patients randomized later (17% vs. 6%; P=0.02)
and a higher risk of NRM (31% vs. 18%; P=0.0006).
Randomization to steroids was not beneficial in these
early grade I GvHD patients, with progression to grades
III-IV in 18% observation versus 16% treatment patients.
In addition, more cases of infectious mortality were found
in patients randomized day 20 or later to the treatment
arm. Univariate and multivariate analysis predicted sur-
vival  by the time of randomization; 4-year survival of
patients randomized before day +20 from transplant was
33% compared to 60% for patients randomized later
(P=0.001), regardless of randomization to the observation
or to the treatment arms. In our data base of 2445 allo-
geneic transplants, the proportion of grade III-IV GvHD in
patients developing GvHD within day 20, between days
21-40, or beyond day 40 is 11%, 9% and 3%, respectively
(P=0.0002), and NRM is 35%, 28% and 25%, respectively
(P=0.0006) (A Bacigalupo et al., 2017, unpublished data), con-
firming other reports on the association of early onset as a
risk factor for grade III-IV GvHD.21  
In conclusion, steroid treatment of grade 1 GvHD pre-
vents  progression to grade II GvHD, but not to grade III-
IV GvHD, and there is no beneficial effect on NRM and
survival. In addition, patients receiving steroids are at a
higher risk of developing infections and have more
adverse events, especially if GvHD develops within day
+20 from transplant.  A small proportion of patients devel-
op life-threatening GvHD, irrespective of early steroid
treatment, suggesting that the severity of GvHD is deter-
mined at onset. Early identification of high-risk patients
with recently described biomarkers,22 and pre-emptive
treatment with non-steroidal agents should be investigat-
ed with the aim of changing the natural course of the dis-
ease.
Study centers 
The following Centers participated in the trial: Ospedale San
Martino, Genova (A Bacigalupo);  Ospedale Ferrarotto, Catania
(G Milone); Ospedale San Camillo, Roma (A Locasciulli);
Ospedale Civile, Pescara (A Santarone); Ospedale Regina
Margherita, Torino (F Fagioli);  Unviersita’ Cattolica, Roma (S
Sica, P Chiusolo); Ospedale S. Croce, Cuneo (N Mordini);
Ospedale Civile, Alessandria (R Sorasio).
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Figure 6. Comparable 5-year overall survival (OS)
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References
1. Bolaños-Meade J, Logan BR, Alousi AM, et
al. Phase 3 clinical trial of
steroids/mycophenolate mofetil vs
steroids/placebo as therapy for acute
GVHD: BMT CTN 0802. Blood. 2014;
124(22):3221-3227
2. Van Lint MT, Milone G, Leotta S, et al.
Treatment of acute graft-versus-host dis-
ease with prednisolone: significant survival
advantage for day +5 responders and no
advantage for nonresponders receiving
anti-thymocyte globulin. Blood. 2006;
107(10):4177-4181. 
3. van Lint MT, Uderzo C, Locasciulli A, et al.
Early treatment of acute graft-versus-host
disease with high- or low-dose 6-methyl-
prednisolone: a multicenter randomized
trial from the Italian Group for Bone
Marrow Transplantation. Blood. 1998;
92(7):2288- 2293.
4. Mielcarek M, Furlong T, Storer BE, et al.
Effectiveness and safety of lower dose
prednisone for initial treatment  of acute
graft-versus-host disease: a randomized
controlled trial . Haematologica. 2015;
100(6);842-848.
5. Mikulska M, Raiola AM, Bruno B, et al.
Risk factors for invasive aspergillosis and
related mortality in recipients of allogeneic
SCT from alternative donors: an analysis of
306 patients. Bone Marrow Transplant.
2009;44(6):361-370.
P=0.3
6. Remberger M, Storer B, Ringdén O,
Anasetti C. Association between pretrans-
plant Thymoglobulin and reduced non-
relapse mortality rate after marrow trans-
plantation from unrelated donors. Bone
Marrow Transplant. 2002;29(5):391-397.
7. Glucksberg H, Storb R, Fefer A, et al.
Clinical manifestations of graft-versus-host
disease in human recipients of marrow
from HL-A-matched sibling donors.
Transplantation. 1974;18(4):295-304.
8. Deeg HJ. How I treat refractory acute
GvHD. Blood. 2007;109(9):4119-4126.
9. Przepiorka D, Weisdorf D, Martin P, et al.
1994 Consensus Conference on Acute
GVHD Grading. Bone Marrow Transplant.
1995;15(6):825-828.
10. Rowlings PA, Przepiorka D, Klein JP, et al.
IBMTR Severity Index for grading acute
graft-versus-host disease: retrospective
comparison with Glucksberg grade. Br J
Haematol. 1997;97(4):855-864. 
11. Martino R, Romero P, Subirá M, et al.
Comparison of the classic Glucksberg crite-
ria and the IBMTR Severity Index for grad-
ing acute graft-versus-host disease follow-
ing HLA-identical sibling stem cell trans-
plantation. International Bone Marrow
Transplant Registry. Bone Marrow
Transplant. 1999;24(3):283-287. 
12. MacMillan ML, Weisdorf DJ, Wagner JE, et
al. Response of 443 patients to steroids as
primary therapy for acute graft-versus-host
disease: comparison of grading systems.
Biol Blood Marrow Transplant. 2002;
8(7):387-394. 
13. MacMillan ML, Robin M, Harris AC, et al.
A Refined Risk Score for Acute Graft-ver-
sus-Host Disease that Predicts Response to
Initial Therapy, Survival, and Transplant-
Related Mortality . Biol Blood and Marrow
Transpl. 2015;21(4):761-767
14. Gratwohl A, Brand R, Apperley J, et al.
Graft vs host diseaseand outcome in HLA
identical sibling transplantation, for chronic
myeloid leukemia. Blood. 2002;
100(12):3877- 3886
15. Levine JE, Braun TM, Harris AC, et al. A
prognostic score for acute graft-versus-host
disease based on biomarkers: a multicentre
study. Lancet Haematol. 2015;2(1):e21-29
16. Gatza E, Braun T, Levine JE, et al.
Etanercept plus topical corticosteroids as
initial therapy for grade one acute graft-ver-
sus-host disease after allogeneic hematopoi-
etic cell transplantation.Biol Blood Marrow
Transplant. 2014; 20(9):1426-1434.
17. Bacigalupo A, Lamparelli T, Milone G, et al
Pre-emptive treatment of acute GVHD: a
randomized multicenter trial of rabbit anti-
thymocyte globulin, given on day+7 after
alternative donor transplants. Bone
Marrow Transplant. 2010;45(2):385-391.
18. Luznik L, O'Donnell PV, Symons HJ, et al.
HLA-haploidentical bone marrow rans-
plantation for hematologic malignancies
using nonmyeloablative conditioning and
high-dose, posttransplantation cyclophos-
phamide. Biol Blood Marrow Transplant.
2008;14(6):641-650.
19. Solomon SR,Sizemore CA, Sanacore M, et
al. Total Body Irradiatione Based
Myeloablative Haploidentical Stem Cell
Transplantation Is a Safe and Effective
Alternative to Unrelated Donor
Transplantation in Patients Without
Matched Sibling Donors. Biol Blood
Marrow Transpl. 2015;21(7):1299-1307
20. Brammer JE, Khouri I, Gaballa S, et al.
Outcomes of Haploidentical Stem Cell
Transplantation for Lymphoma with
Melphalan-Based Conditioning. Biol Blood
Marrow Transpl. 2016;22(3):493-498.
21. Kanakry CG, Ganguly S, Zahurak M, et al.
Aldehyde dehydrogenase expression drives
human regulatory T cell resistance to post-
transplantation cyclophosphamide. Sci
Transl Med. 2013;5(211):211ra157.
22. Saliba RM, De Lima M,Giralt S, et al.
Hyperacute GVHD: risk factors, outcomes,
and clinical implications. Blood. 2007;
109(7):2751-2758.
23. Hartwell MJ, Özbek U, Holler E, et al. An
early-biomarker  algorithm predicts lethal
graft-versus-host disease and survival. JCI
Insight. 2017;2(3):e89798. 
Steroid treatment of GvHD grade I 
haematologica | 2017; 102(12) 2133
